X

Trial Profile

A Phase 1/2 Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 19 Jan 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Elexacaftor (Primary) ; Deutivacaftor; Ivacaftor; Ivacaftor/tezacaftor; Tezacaftor
Indications Cystic fibrosis
Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
Sponsors Vertex Pharmaceuticals

Most Recent Events

18 Oct 2018 Results presented in a Vertex Pharmaceuticals Media Release.
18 Oct 2018 According to a Vertex Pharmaceuticals media release, results are being presented at the 32ndNorth American Cystic Fibrosis Conference.
18 Oct 2018 Results published in the New England Journal of Medicine

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com